Skip to Main Content

Paper Details

Immune Predictors of Mortality After Ribonucleic Acid Virus Infection.
J Infect Dis
8
2020
Ribonucleic, West Nile virus, coronavirus, humans, influenza, mice, severe acute respiratory syndrome
Animals, Collaborative Cross Mice, Cytokines, Disease Models, Animal, Female, Humans, Influenza A virus, Influenza, Human, Male, Mice, Mortality, Orthomyxoviridae Infections, RNA, RNA Virus Infections, Severe Acute Respiratory Syndrome, Severe acute respiratory syndrome-related coronavirus, T-Lymphocytes, Viral Vaccines, West Nile Fever, West Nile virus
Author NameAffiliation
Jessica B GrahamFred Hutchinson Cancer Research Center
Jessica L SwartsFred Hutchinson Cancer Research Center
Vineet D MenacheryUniversity of North Carolina at Chapel Hill
Vineet D MenacheryUniversity of Texas Medical Center
Lisa E GralinskiUniversity of North Carolina at Chapel Hill
Lisa E GralinskiUniversity of North Carolina at Chapel Hill
Alexandra Sch??ferUniversity of North Carolina at Chapel Hill
Kenneth S PlanteUniversity of North Carolina at Chapel Hill
Kenneth S PlanteUniversity of North Carolina at Chapel Hill
Clayton R MorrisonUniversity of North Carolina at Chapel Hill
Kathleen M VossCenter for Innate Immunity and Immune Disease, University of Washington School of Medicine
Richard GreenCenter for Innate Immunity and Immune Disease, University of Washington School of Medicine
Gabrielle ChoonooDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Sophia JengDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Darla R MillerUniversity of North Carolina at Chapel Hill
Darla R MillerUniversity of North Carolina at Chapel Hill
Michael A MooneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Michael A MooneyOHSU Knight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyDepartment of Medical Informatics and Clinical Epidemiology, Oregon Health & Science University
Shannon K McWeeneyOHSU Knight Cancer Institute, Oregon Health & Science University
Shannon K McWeeneyOregon Clinical and Translational Research Institute, Oregon Health & Science University
Martin T FerrisUniversity of North Carolina at Chapel Hill
Martin T FerrisUniversity of North Carolina at Chapel Hill
Fernando Pardo-Manuel de VillenaUniversity of North Carolina at Chapel Hill
Fernando Pardo-Manuel de VillenaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Fernando Pardo-Manuel de VillenaUniversity of North Carolina at Chapel Hill
Fernando Pardo-Manuel de VillenaLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Michael GaleCenter for Innate Immunity and Immune Disease, University of Washington School of Medicine
Mark T HeiseUniversity of North Carolina at Chapel Hill
Mark T HeiseLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Mark T HeiseUniversity of North Carolina at Chapel Hill
Mark T HeiseLineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Ralph S BaricUniversity of North Carolina at Chapel Hill
Jennifer M LundFred Hutchinson Cancer Research Center
Jennifer M LundUniversity of Washington
  • 1 - 36

Datasets